Abstract Library

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4499 Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study

Introduction: The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.

Conference:

Presenting Author: Klaas L

Authors: Barsch M, Graessel L, Metzger P, Klaas L, Schulz L,

Keywords: Neuroendocrine neoplasm, Molecular Tumour Board, personalised medicine, precision oncology, targeted therapy,

#4496 ATRX, DAXX, and menin immunohistochemistry identify prognostic relevant non-functioning neuroendocrine tumours subgroups

Introduction: Non-functioning pancreatic neuroendocrine tumours (NF-pNETs) are rare tumours with a variable prognosis. Recent studies have identified prognostic subgroups based on ATRX, DAXX and MEN1 mutations along with chromosomal aneuploidies.

Conference:

Presenting Author: Verschuur A

Authors: Verschuur A, Jairam J, Eldem B, Singhi A, Hackeng W,

Keywords: pancreatic neuroendocrine tumour, ATRX, DAXX, MEN1, menin, biomarker,

#4446 Uncommon ophthalmic presentation of a small bowel neuroendocrine tumour: Case report

Introduction: Neuroendocrine tumours (NETs), including carcinoid tumours, are slow-growing neoplasms commonly originating in the gastrointestinal tract or bronchus, but they can also arise in other sites. Due to their indolent nature, the majority of NETs are diagnosed at an advanced stage, typically to the lymph nodes, liver, or bones.

Conference:

Presenting Author:

Authors: Hamidatou K, Behourah Z, Ahed Messaoud M, Megaiz A, Lechar M,

Keywords: Neuroendocrine tumour, Carcinoid tumour, Orbital metastasis, somatostatin analogue injection,

#4368 Surgical and multidisciplinary management of pancreatic neuroendocrine tumours with liver metastases: Insights from a high-volume centre

Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare, with liver metastases posing significant prognostic challenges. MEN1-associated pNETs often present with multifocal and complex disease, requiring a tailored, multidisciplinary approach.

Conference:

Presenting Author: Yuntao B

Authors: Yuntao B, Chunhui Y, Lei L,

Keywords: Pancreatic Neuroendocrine Tumour, Liver Metastasis, MEN1, Multidisciplinary Team, Surgical Resection, Ki-67 Index, SSA, PRRT,